Compare CPIX & FMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPIX | FMN |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 87.8M |
| IPO Year | 2007 | N/A |
| Metric | CPIX | FMN |
|---|---|---|
| Price | $3.18 | $10.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 24.9K |
| Earning Date | 03-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.86% |
| EPS Growth | ★ 58.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,010,949.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.75 | N/A |
| 52 Week Low | $1.85 | $10.11 |
| 52 Week High | $6.27 | $11.38 |
| Indicator | CPIX | FMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 47.18 |
| Support Level | $2.95 | $10.56 |
| Resistance Level | $3.69 | $11.10 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 75.00 | 59.02 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.